Nocturnal akathisia in Parkinson's disease: treatment with clozapine.
We present the results obtained using low doses of clozapine (mean dose 26.4 mg at bedtime) in the treatment of nocturnal akathisia in nine patients with Parkinson's disease for a mean period of 12.5 months. The results were excellent in all the patients. Furthermore, three patients experienced a remarkable improvement in rest tremor and in five patients the confusional state that accompanied the akathisia also disappeared. No serious side-effects were observed. We believe that clozapine is a very useful drug for the relief of nocturnal akathisia in parkinsonian subjects.
Linazasoro
G
G
Section of Neurology, Hospital Nuestra Senora de Arantzazu, San Sebastián, Spain.
Martí Massó
J F
JF
Suárez
J A
JA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001545:Benserazide / Q000008:administration & dosage / Q000009:adverse effects; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects; D002940:Circadian Rhythm / Q000187:drug effects; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D003221:Confusion / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D011595:Psychomotor Agitation / Q000188:drug therapy*; D012893:Sleep Wake Disorders / Q000188:drug therapy*
D001545:Benserazide; D003024:Clozapine; D002230:Carbidopa